1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Ward, B.P.
Ma, D.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C4 H9 N O2
103.120
n
ALPHA-AMINOISOBUTYRIC ACID
L-peptide linking
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H9 N O4
147.129
GAMMA-L-GLUTAMIC ACID
L-GLUTAMIC ACID
L-gamma-peptide, C-delta linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
H2 N
16.023
AMINO GROUP
non-polymer
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C16 H32 O2
256.424
PALMITIC ACID
non-polymer
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
To be Published
0353
Structural Changes Associated with Peptide Lipidation Broaden Biological Function
10.2210/pdb2m5q/pdb
pdb_00002m5q
3446.849
Glucagon
1
syn
polymer
147.129
GAMMA-L-GLUTAMIC ACID
2
syn
non-polymer
256.424
PALMITIC ACID
1
syn
non-polymer
no
yes
H(AIB)QGTFTSDYSKKLD(AIB)RRAQDFVQWLMNT(NH2)
HAQGTFTSDYSKKLDARRAQDFVQWLMNTX
X
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_database_status
struct_conn
struct_ref_seq_dif
repository
Initial release
Database references
Derived calculations
Other
1
0
2013-03-27
1
1
2023-06-14
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
_struct_conn.pdbx_dist_value
_struct_conn.pdbx_leaving_atom_flag
_struct_conn.ptnr1_auth_comp_id
_struct_conn.ptnr1_auth_seq_id
_struct_conn.ptnr1_label_atom_id
_struct_conn.ptnr1_label_comp_id
_struct_conn.ptnr1_label_seq_id
_struct_conn.ptnr2_auth_comp_id
_struct_conn.ptnr2_auth_seq_id
_struct_conn.ptnr2_label_asym_id
_struct_conn.ptnr2_label_atom_id
_struct_conn.ptnr2_label_comp_id
_struct_conn.ptnr2_label_seq_id
_struct_ref_seq_dif.details
HELIX
DETERMINATION METHOD: AUTHOR DETERMINED
BMRB
Y
RCSB
2013-03-04
REL
REL
REL
REL
GGL
GAMMA-L-GLUTAMIC ACID
PLM
PALMITIC ACID
9606
human
Homo sapiens
sample
structures with the lowest energy
100
10
2D 1H-1H TOCSY
2D 1H-1H NOESY
0.7
mM
0
5.0
ambient
298
K
simulated annealing
1
lowest energy
0.7 mM protein, 95% [U-100% 2H] TFE/5% H2O
95% [U-100% 2H] TFE/5% H2O
BRUNGER
refinement
XPLOR-NIH
600
Varian
Varian Uniform NMR System
GGL
101
2
GGL
GGL
101
X
GGL
102
2
GGL
GGL
102
X
PLM
103
3
PLM
PLM
103
X
HIS
1
n
1
HIS
1
X
AIB
2
n
2
AIB
2
X
GLN
3
n
3
GLN
3
X
GLY
4
n
4
GLY
4
X
THR
5
n
5
THR
5
X
PHE
6
n
6
PHE
6
X
THR
7
n
7
THR
7
X
SER
8
n
8
SER
8
X
ASP
9
n
9
ASP
9
X
TYR
10
n
10
TYR
10
X
SER
11
n
11
SER
11
X
LYS
12
n
12
LYS
12
X
LYS
13
n
13
LYS
13
X
LEU
14
n
14
LEU
14
X
ASP
15
n
15
ASP
15
X
AIB
16
n
16
AIB
16
X
ARG
17
n
17
ARG
17
X
ARG
18
n
18
ARG
18
X
ALA
19
n
19
ALA
19
X
GLN
20
n
20
GLN
20
X
ASP
21
n
21
ASP
21
X
PHE
22
n
22
PHE
22
X
VAL
23
n
23
VAL
23
X
GLN
24
n
24
GLN
24
X
TRP
25
n
25
TRP
25
X
LEU
26
n
26
LEU
26
X
MET
27
n
27
MET
27
X
ASN
28
n
28
ASN
28
X
THR
29
n
29
THR
29
X
NH2
30
n
30
NH2
30
X
author_defined_assembly
1
monomeric
X
AIB
2
ALPHA-AMINOISOBUTYRIC ACID
A
AIB
2
ALA
X
AIB
16
ALPHA-AMINOISOBUTYRIC ACID
A
AIB
16
ALA
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
2
X
X
H2
H
HIS
AIB
1
2
1.31
6
X
X
H2
H
HIS
AIB
1
2
1.30
7
X
X
O
H
LYS
ARG
13
17
1.60
1
X
GLN
3
-53.79
-9.96
1
X
THR
7
-103.56
-70.46
1
X
ASP
9
-73.09
37.77
1
X
TYR
10
-149.40
26.80
1
X
LYS
13
-133.07
-75.35
1
X
ASP
15
-76.05
45.55
1
X
AIB
16
176.54
-22.23
1
X
PHE
22
-76.58
-72.62
1
X
VAL
23
-55.09
-1.34
2
X
AIB
2
64.28
-156.44
2
X
GLN
3
53.71
-83.61
2
X
THR
7
79.18
-58.79
2
X
SER
8
-53.99
-70.88
2
X
TYR
10
-67.33
-174.20
2
X
SER
11
59.22
4.95
2
X
LYS
12
-135.79
-63.22
2
X
LYS
13
-85.95
-88.86
2
X
ASP
15
-74.72
44.59
2
X
AIB
16
178.67
-23.80
2
X
ASP
21
-53.92
-8.34
2
X
PHE
22
-105.13
-70.09
2
X
VAL
23
-55.87
-0.40
3
X
AIB
2
-163.66
-14.70
3
X
GLN
3
41.52
92.79
3
X
SER
8
-41.73
-79.10
3
X
TYR
10
-41.91
98.78
3
X
SER
11
169.23
-40.00
3
X
LYS
12
-116.19
58.91
3
X
LYS
13
-171.76
-58.54
3
X
AIB
16
176.89
-15.86
3
X
GLN
20
-67.90
-70.88
3
X
PHE
22
-80.93
-73.40
3
X
VAL
23
-54.50
-2.11
3
X
MET
27
-95.19
-156.84
3
X
ASN
28
59.55
2.80
4
X
AIB
2
61.11
125.51
4
X
GLN
3
-72.87
45.06
4
X
THR
5
52.56
14.60
4
X
SER
11
-54.44
-7.88
4
X
LYS
13
-44.04
-79.55
4
X
ASP
15
-73.89
46.34
4
X
AIB
16
177.41
-24.64
4
X
ASP
21
-54.55
-7.74
4
X
PHE
22
-105.50
-70.21
4
X
VAL
23
-55.79
-0.42
4
X
ASN
28
-101.10
43.33
5
X
GLN
3
63.22
-71.74
5
X
PHE
6
58.31
129.34
5
X
THR
7
-93.88
-81.64
5
X
SER
11
164.07
-42.16
5
X
AIB
16
178.10
-41.68
5
X
PHE
22
-108.49
-66.26
5
X
VAL
23
-58.15
1.96
5
X
MET
27
-91.37
-153.95
6
X
GLN
3
70.37
-62.94
6
X
PHE
6
-168.41
-11.36
6
X
SER
8
-49.20
-12.56
6
X
TYR
10
-145.42
23.48
6
X
LYS
13
-137.45
-80.21
6
X
AIB
16
178.02
-51.63
6
X
ALA
19
-135.80
-35.52
6
X
ASP
21
-53.58
-8.67
6
X
PHE
22
-105.53
-69.89
6
X
VAL
23
-56.02
-0.32
6
X
ASN
28
-95.70
31.35
7
X
AIB
2
172.17
-72.32
7
X
GLN
3
-50.68
-9.11
7
X
THR
7
-41.06
-70.39
7
X
SER
8
-73.52
27.69
7
X
ASP
9
-158.04
17.50
7
X
LYS
12
-145.16
-44.55
7
X
LYS
13
-100.26
-90.90
7
X
ASP
15
-77.87
45.78
7
X
AIB
16
177.87
-50.66
7
X
ALA
19
-139.96
-33.42
7
X
ASP
21
-56.88
-5.67
7
X
PHE
22
-107.31
-71.14
7
X
VAL
23
-55.27
-0.83
8
X
AIB
2
67.75
-144.46
8
X
GLN
3
33.04
49.79
8
X
THR
7
-93.95
-67.73
8
X
SER
8
-63.44
72.23
8
X
ASP
9
165.33
-12.53
8
X
LYS
13
-172.57
-45.05
8
X
ASP
15
-75.30
22.27
8
X
AIB
16
-156.85
-1.58
8
X
GLN
20
-70.46
-75.66
8
X
PHE
22
-92.11
-72.99
8
X
VAL
23
-54.00
-1.93
8
X
ASN
28
-97.06
-65.06
9
X
GLN
3
-70.30
40.33
9
X
LYS
12
-111.08
73.79
9
X
LYS
13
-163.25
-52.18
9
X
AIB
16
177.07
-30.52
9
X
GLN
20
-66.82
-74.41
9
X
PHE
22
-76.28
-73.25
9
X
VAL
23
-56.91
0.32
10
X
THR
7
-43.83
169.56
10
X
SER
8
78.13
-20.33
10
X
SER
11
80.60
7.54
10
X
LYS
13
-103.38
-91.47
10
X
ASP
15
-77.30
47.37
10
X
AIB
16
-179.67
-17.32
10
X
PHE
22
-81.63
-72.39
10
X
VAL
23
-55.45
-0.79
Solution structure of lipidated glucagon analog in d-TFE
1
N
N
2
N
N
2
N
N
3
N
N
X
PHE
6
A
PHE
6
HELX_P
X
LEU
14
A
LEU
14
5
1
9
X
ARG
17
A
ARG
17
HELX_P
X
ASN
28
A
ASN
28
1
2
12
covale
1.329
both
X
HIS
1
A
C
HIS
1
1_555
X
AIB
2
A
N
AIB
2
1_555
covale
1.328
both
X
AIB
2
A
C
AIB
2
1_555
X
GLN
3
A
N
GLN
3
1_555
covale
1.329
one
X
LYS
13
A
NZ
LYS
13
1_555
X
GGL
101
B
CD
GGL
1_555
covale
1.329
both
X
ASP
15
A
C
ASP
15
1_555
X
AIB
16
A
N
AIB
16
1_555
covale
1.329
both
X
AIB
16
A
C
AIB
16
1_555
X
ARG
17
A
N
ARG
17
1_555
covale
1.304
both
X
THR
29
A
C
THR
29
1_555
X
NH2
30
A
N
NH2
30
1_555
covale
1.329
both
X
GGL
101
B
N
GGL
1_555
X
GGL
102
C
CD
GGL
1_555
covale
1.329
both
X
GGL
102
C
N
GGL
1_555
X
PLM
103
D
C1
PLM
1_555
LIPID BINDING PROTEIN
GLUCAGON, DIABETES, OBESITY, LIPIDATED, LIPID BINDING PROTEIN
GLUC_HUMAN
UNP
1
53
P01275
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
53
81
2M5Q
1
29
P01275
X
1
1
29
1
SER
engineered mutation
AIB
2
2M5Q
X
P01275
UNP
54
2
1
TYR
engineered mutation
LYS
13
2M5Q
X
P01275
UNP
65
13
1
SER
engineered mutation
AIB
16
2M5Q
X
P01275
UNP
68
16
1
amidation
NH2
30
2M5Q
X
P01275
UNP
30
BINDING SITE FOR LINKED RESIDUES X 101 to 103
Software
3
X
ASP
9
A
ASP
9
3
1_555
X
TYR
10
A
TYR
10
3
1_555
X
LYS
13
A
LYS
13
3
1_555